Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBLearning to live with both sleep apnea and pulmonary fibrosis. Living with pulmonary fibrosis is already a daunting challenge, but when coupled with a sleep disorder like sleep apnea, the burden becomes even heavier. Sleep apnea, a condition in which breathing repeatedly stops and starts during sleep, can significantly impact both sleep quality ...
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with idiopathic PF (IPF) and progressive PF. Patients were assigned randomly to receive either 30 or 60 mg of the therapy, or a placebo ...
Zelasudil wins FDA orphan drug status as IPF treatment candidate
WEBAug 25, 2023 · In preclinical models, zelasudil showed the ability to lessen scarring — and it was generally well tolerated in a Phase 1 study of healthy volunteers. “Selectively targeting ROCK2 is an exciting, novel approach which could provide a new treatment option for patients with IPF, and with potential applications in other interstitial lung diseases and cancer-associated fibrosis,” Robertson said.
Primary goal met for IPF in Phase 3 clinical trial of nerandomilast
WEB2 days ago · A Phase 3 clinical trial testing Boehringer Ingelheim ’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the therapy outperformed a placebo at improving lung function or preventing its decline after a year, recently announced top-line data shows.
Oral BMS-986278 slows lung decline in progressive PF, Phase 2...
WEBSep 25, 2023 · These findings are consistent with previously reported data from a group of idiopathic pulmonary fibrosis (IPF) patients also participating in the clinical trial, whose lung function decline decreased by 62% with treatment at that dose.. Study results support moving BMS-986278 into global Phase 3 testing in a trial program being called ALOFT, according to the therapy’s developer, Bristol ...
Study: ENV-101 improves IPF lung function, reverses fibrosis
WEBby Andrea Lobo June 7, 2024. Endeavor BioMedicines ’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The results, which also showed the treatment had an acceptable tolerability profile, were presented in a late ...
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
WEBRecent Posts. $15K award goes to researcher for work into IPF disease risk factors September 20, 2024; Learning to live with both sleep apnea and pulmonary fibrosis September 17, 2024; Navigating emotional ups and downs on my IPF journey September 17, 2024; Phase 2b trial tests AP01, inhaled pirfenidone, in progressive PF September 13, 2024; A new twist in my journey: Familial idiopathic ...
Saracatinib as Effective, or Superior to Ofev, Esbriet in IPF...
WEBAug 30, 2022 · Saracatinib worked as well or better than Ofev or Esbriet at reducing tissue scarring, or fibrosis, in cell and animal models of IPF, a study showed.. The oral therapy was identified as an IPF treatment candidate based on a computational approach that analyzed the potential anti-fibrotic effects of several medications developed for …
First Patient Enrolled in Phase 3 Trial Testing BI 1015550
WEBOct 28, 2022 · Earlier this year, final data from a Phase 2 clinical trial (NCT04419506) demonstrated that BI 1015550 slowed lung function decline in 147 IPF patients, ages 40 and older, regardless of whether they were receiving anti-fibrotic therapies. “We’re excited to build on the positive Phase 2 results so we can better understand the long-term efficacy, safety and tolerability of this ...
IPF Patients Live Longer on Ofev Compared with Placebo, Analysis …
WEBApr 16, 2019 · The analysis included data collected from a total of 1,126 IPF patients (mean age of 66.9 years), who were treated twice daily with 150 mg of Ofev, and 565 patients treated with a placebo. Participants received the treatment for a mean period of 27.7 months, with some patients receiving the treatment for a maximum of 93.1 months.